{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T16:09:37Z","timestamp":1791043777690,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,10,20]],"date-time":"2012-10-20T00:00:00Z","timestamp":1350691200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1007\/s11060-012-0995-0","type":"journal-article","created":{"date-parts":[[2012,10,19]],"date-time":"2012-10-19T12:03:53Z","timestamp":1350648233000},"page":"97-102","source":"Crossref","is-referenced-by-count":55,"title":["Mibefradil, a novel therapy for glioblastoma multiforme: cell cycle synchronization and interlaced therapy in a murine model"],"prefix":"10.1007","volume":"111","author":[{"given":"Stephen T.","family":"Keir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry S.","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Reardon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darell D.","family":"Bigner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lloyd A.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,10,20]]},"reference":[{"key":"995_CR1","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987\u2013996","journal-title":"N Engl J Med"},{"key":"995_CR2","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997\u20131003","journal-title":"N Engl J Med"},{"key":"995_CR3","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2165\/00024669-200201010-00006","volume":"1","author":"MJM Darkes","year":"2002","unstructured":"Darkes MJM, Plosker GL, Jarvis B (2002) Temozolomide: a review of its use in the treatment of malignant gliomas, malignant melanoma and other advanced cancers. Am J Cancer 1:55\u201380","journal-title":"Am J Cancer"},{"key":"995_CR4","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.phrs.2007.08.003","volume":"56","author":"F Marchesi","year":"2007","unstructured":"Marchesi F, Turriziani M, Tortorelli G, Avvisati G, Torino F, De Vecchis L (2007) Triazene compounds: mechanism of action and related DNA repair systems. Pharmacol Res 56:275\u2013287","journal-title":"Pharmacol Res"},{"key":"995_CR5","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ceca.2006.04.017","volume":"40","author":"P Lory","year":"2006","unstructured":"Lory P, Bidaud I, Chemin J (2006) T-type calcium channels in differentiation and proliferation. Cell Calcium 40:135\u2013146","journal-title":"Cell Calcium"},{"key":"995_CR6","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ceca.2004.05.001","volume":"36","author":"LS Gray","year":"2004","unstructured":"Gray LS, Perez-Reyes E, Gomora JC et al (2004) The role of voltage gated T-type Ca2+ channel isoforms in mediating \u201ccapacitative\u201d Ca2+ entry in cancer cells. Cell Calcium 36:489\u2013497","journal-title":"Cell Calcium"},{"key":"995_CR7","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.2174\/0929867043365008","volume":"11","author":"L Munaron","year":"2004","unstructured":"Munaron L, Antoniotti S, Fiorio Pla A, Lovisolo D (2004) Blocking Ca2+entry: a way to control cell proliferation. Curr Med Chem 11:1533\u20131543","journal-title":"Curr Med Chem"},{"key":"995_CR8","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1097\/00004872-199715055-00004","volume":"15","author":"JP Clozel","year":"1997","unstructured":"Clozel JP, Ertel EA, Ertel SI (1997) Discovery and main pharmacological properties of mibefradil (Ro 40-5967), the first selective T-type calcium channel blocker. J Hypertens Suppl 15:S17\u2013S25","journal-title":"J Hypertens Suppl"},{"key":"995_CR9","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ceca.2004.07.002","volume":"37","author":"A Panner","year":"2005","unstructured":"Panner A, Cribbs LL, Zainelli GM, Origitano TC, Singh S, Wurster RD (2005) Variation of T-type calcium channel protein expression affects cell division of cultured tumor cells. Cell Calcium 37:105\u2013119","journal-title":"Cell Calcium"},{"key":"995_CR10","first-page":"4189","volume":"48","author":"HS Friedman","year":"1988","unstructured":"Friedman HS, Colvin OM, Skapek SX et al (1988) Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents. Cancer Res 48:4189\u20134195","journal-title":"Cancer Res"},{"key":"995_CR11","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1097\/00006123-199911000-00039","volume":"45","author":"IF Pollack","year":"1999","unstructured":"Pollack IF, Bredel M, Erff M, Hamilton AD, Sebti SM (1999) Inhibition of Ras and related guanosine triphosphate-dependent proteins as a therapeutic strategy for blocking malignant glioma growth: II\u2014preclinical studies in a nude mouse model. Neurosurgery 45:1208\u20131214; discussion 14\u201315","journal-title":"Neurosurgery"},{"key":"995_CR12","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/biomet\/52.1-2.203","volume":"52","author":"EA Gehan","year":"1965","unstructured":"Gehan EA (1965) A Generalized Wilcoxon Test for Comparing Arbitrarily Singly-Censored Samples. Biometrika 52:203\u2013223","journal-title":"Biometrika"},{"key":"995_CR13","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(05)78800-0","volume":"351","author":"AL Po","year":"1998","unstructured":"Po AL, Zhang WY (1998) What lessons can be learnt from withdrawal of mibefradil from the market? Lancet 351:1829\u20131830","journal-title":"Lancet"},{"key":"995_CR14","doi-asserted-by":"crossref","first-page":"40C","DOI":"10.1016\/S0002-9149(97)00569-9","volume":"80","author":"I Kobrin","year":"1997","unstructured":"Kobrin I, Charlon V, Lindberg E, Pordy R (1997) Safety of mibefradil, a new once-a-day, selective T-type calcium channel antagonist. Am J Cardiol 80:40C\u201346C","journal-title":"Am J Cardiol"},{"key":"995_CR15","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1161\/01.ATV.15.8.1161","volume":"15","author":"R Schmitt","year":"1995","unstructured":"Schmitt R, Clozel JP, Iberg N, Buhler FR (1995) Mibefradil prevents neointima formation after vascular injury in rats. Possible role of the blockade of the T-type voltage-operated calcium channel. Arterioscler Thromb Vasc Biol 15:1161\u20131165","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"995_CR16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/BF00823586","volume":"10","author":"R Schmitt","year":"1996","unstructured":"Schmitt R, Clozel JP, Iberg N, Buhler FR (1996) Prevention of neointima formation by mibefradil after vascular injury in rats: comparison with ACE inhibition. Cardiovasc Drugs Ther 10:101\u2013105","journal-title":"Cardiovasc Drugs Ther"},{"key":"995_CR17","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1161\/01.ATV.15.8.1161","volume":"15","author":"R Schmitt","year":"1995","unstructured":"Schmitt R, Clozel JP, Iberg N, Buhler FR (1995) Mibefradil prevents neointima formation after vascular injury in rats. Possible role of the blockade of the T-type voltage-operated calcium channel. Arterioscler Thromb Vasc Biol 15:1161\u20131165","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"995_CR18","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/paa.1999.111.5.429","volume":"111","author":"JP Clozel","year":"1999","unstructured":"Clozel JP, Ertel EA, Ertel SI (1999) Voltage-gated T-type Ca 2+ channels and heart failure. Proc Assoc Am Phys 111:429\u2013437","journal-title":"Proc Assoc Am Phys"},{"key":"995_CR19","first-page":"29","volume":"21","author":"EE Vokes","year":"1994","unstructured":"Vokes EE (1994) The promise of biochemical modulation in combined modality therapy. Semin Oncol 21:29\u201333","journal-title":"Semin Oncol"},{"key":"995_CR20","first-page":"327","volume":"13","author":"RS Camplejohn","year":"1980","unstructured":"Camplejohn RS (1980) A critical review of the use of vincristine (VCR) as a tumour cell synchronizing agent in cancer therapy. Cell Tissue Kinet 13:327\u2013335","journal-title":"Cell Tissue Kinet"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-012-0995-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-012-0995-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-012-0995-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T20:55:16Z","timestamp":1562273716000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-012-0995-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,20]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["995"],"URL":"https:\/\/doi.org\/10.1007\/s11060-012-0995-0","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,20]]}}}